A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor

LESSONS LEARNED. The combination of pexidartinib and binimetinib was safe and tolerable and demonstrated encouraging signs of efficacy in two patients with advanced gastrointestinal stromal tumor (GIST) refractory to tyrosine kinase inhibitors (TKIs). Molecular profiling of GISTs at diagnosis and up...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Rosenbaum, Evan, Kelly, Ciara, D'Angelo, Sandra P., Dickson, Mark A., Gounder, Mrinal, Keohan, Mary L., Movva, Sujana, Condy, Mercedes, Adamson, Travis, Mcfadyen, Chloe R., Antonescu, Christina R., Hwang, Sinchun, Singer, Sam, Qin, Li‐Xuan, Tap, William D., Chi, Ping
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795162/
https://ncbi.nlm.nih.gov/pubmed/31213500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0418
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars